Targets › NPR1
1 program from 1 company in 1 trial: 1 Phase 1; Cardiovascular; next expected readout Dec 2030.
Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Plays an essential role in the regulation of endothelial cell senescence and vascular aging. (UniProt, P16066)
Open in Phaseline: the race on NPR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Oslo University Hospital | Nesiritide Atrial natriuretic peptide receptor A agonist | NPR1 | Phase 1 | Hypertension | Dec 2030 |
Hypertension (1)
protein or peptide (1)
Oslo University Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.